Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of VG161 and find recommended dose of VG161. Part 2: This part is extended dose design to determine the effectiveness of VG161.

Trial Details

NCT ID
NCT04806464
Phase
PHASE1
Sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • According to 'The Diagnostic and Therapeutic Criteria for Primary Liver Cancer' (NMPA, 2019 Edition), subject with advanced primary hepatocellular …
  • There are tumor lesions intrahepatic and / or extrahepatic metastases that can be injected under B ultrasound and meet the volume requirements of t…
  • Eastern Cooperative Oncology Group (ECOG) scores 0 or 1.
  • Life expectancy is at least 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →